Oramed Pharmaceuticals (ORMP) Competitors $3.99 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.85 -0.14 (-3.56%) As of 05/22/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. AVTE, ACRS, GYRE, CYRX, and CTMXShould you buy Oramed Pharmaceuticals stock or one of its competitors? MarketBeat compares Oramed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oramed Pharmaceuticals include Aerovate Therapeutics (AVTE), Aclaris Therapeutics (ACRS), Gyre Therapeutics (GYRE), CryoPort (CYRX), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. ORMP vs. AVTEORMP vs. ACRSORMP vs. GYREORMP vs. CYRXORMP vs. CTMXHow does Oramed Pharmaceuticals compare to Aerovate Therapeutics?Aerovate Therapeutics (NASDAQ:AVTE) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Which has better valuation and earnings, AVTE or ORMP? Oramed Pharmaceuticals has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/AOramed Pharmaceuticals$2M81.66$64.05M$2.591.54 Does the media favor AVTE or ORMP? In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 0.11 beat Aerovate Therapeutics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Oramed Pharmaceuticals Neutral Do institutionals & insiders have more ownership in AVTE or ORMP? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, AVTE or ORMP? Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Do analysts prefer AVTE or ORMP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AVTE or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -5.37% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Oramed Pharmaceuticals N/A -5.37%-4.83% SummaryOramed Pharmaceuticals beats Aerovate Therapeutics on 11 of the 12 factors compared between the two stocks.How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?Aclaris Therapeutics (NASDAQ:ACRS) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Do insiders and institutionals hold more shares of ACRS or ORMP? 98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 5.6% of Aclaris Therapeutics shares are held by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ACRS or ORMP? Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Is ACRS or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Oramed Pharmaceuticals' return on equity of -5.37% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-832.58% -55.89% -38.49% Oramed Pharmaceuticals N/A -5.37%-4.83% Which has higher valuation & earnings, ACRS or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$7.83M80.62-$64.92M-$0.56N/AOramed Pharmaceuticals$2M81.66$64.05M$2.591.54 Do analysts rate ACRS or ORMP? Aclaris Therapeutics currently has a consensus price target of $11.29, suggesting a potential upside of 149.68%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ACRS or ORMP? In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 0 mentions for Aclaris Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 0.11 beat Aclaris Therapeutics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Aclaris Therapeutics Neutral Oramed Pharmaceuticals Neutral SummaryOramed Pharmaceuticals beats Aclaris Therapeutics on 11 of the 17 factors compared between the two stocks.How does Oramed Pharmaceuticals compare to Gyre Therapeutics?Gyre Therapeutics (NASDAQ:GYRE) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders and institutionals have more ownership in GYRE or ORMP? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, GYRE or ORMP? Gyre Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Is GYRE or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Oramed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-5.44% 3.13% 2.67% Oramed Pharmaceuticals N/A -5.37%-4.83% Which has preferable earnings and valuation, GYRE or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$116.59M5.04$5.03M-$0.09N/AOramed Pharmaceuticals$2M81.66$64.05M$2.591.54 Do analysts prefer GYRE or ORMP? Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 180.53%. Given Gyre Therapeutics' higher possible upside, research analysts plainly believe Gyre Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to GYRE or ORMP? In the previous week, Gyre Therapeutics had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for Gyre Therapeutics and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.11 beat Gyre Therapeutics' score of -0.39 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryGyre Therapeutics beats Oramed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.How does Oramed Pharmaceuticals compare to CryoPort?CryoPort (NASDAQ:CYRX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders and institutionals have more ownership in CYRX or ORMP? 92.9% of CryoPort shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 10.0% of CryoPort shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to CYRX or ORMP? In the previous week, CryoPort had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for CryoPort and 2 mentions for Oramed Pharmaceuticals. CryoPort's average media sentiment score of 0.12 beat Oramed Pharmaceuticals' score of 0.11 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer CYRX or ORMP? CryoPort currently has a consensus price target of $14.69, indicating a potential upside of 4.91%. Given CryoPort's stronger consensus rating and higher possible upside, research analysts plainly believe CryoPort is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, CYRX or ORMP? CryoPort has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoPort$176.18M4.00$78.30M$1.3510.37Oramed Pharmaceuticals$2M81.66$64.05M$2.591.54 Which has more risk and volatility, CYRX or ORMP? CryoPort has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Is CYRX or ORMP more profitable? CryoPort has a net margin of 41.57% compared to Oramed Pharmaceuticals' net margin of 0.00%. Oramed Pharmaceuticals' return on equity of -5.37% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets CryoPort41.57% -7.92% -4.79% Oramed Pharmaceuticals N/A -5.37%-4.83% SummaryCryoPort beats Oramed Pharmaceuticals on 12 of the 16 factors compared between the two stocks.How does Oramed Pharmaceuticals compare to CytomX Therapeutics?CytomX Therapeutics (NASDAQ:CTMX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Does the media favor CTMX or ORMP? In the previous week, CytomX Therapeutics had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Oramed Pharmaceuticals. CytomX Therapeutics' average media sentiment score of 0.65 beat Oramed Pharmaceuticals' score of 0.11 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, CTMX or ORMP? CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Do analysts prefer CTMX or ORMP? CytomX Therapeutics presently has a consensus price target of $12.10, indicating a potential upside of 221.81%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is CTMX or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Oramed Pharmaceuticals' return on equity of -5.37% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics-166.40% -36.61% -28.02% Oramed Pharmaceuticals N/A -5.37%-4.83% Which has stronger valuation and earnings, CTMX or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$76.20M8.40-$17.37M-$0.41N/AOramed Pharmaceuticals$2M81.66$64.05M$2.591.54 Do insiders and institutionals believe in CTMX or ORMP? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryCytomX Therapeutics beats Oramed Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition ExportMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.29M$8.52B$6.45B$12.34BDividend Yield6.27%2.50%2.76%5.28%P/E Ratio1.5413.1617.9322.89Price / Sales81.668.28553.9286.28Price / Cash43.9817.1143.4956.67Price / Book0.694.0610.377.14Net Income$64.05M$224.05M$3.57B$335.98M7 Day Performance-6.99%4.68%6.01%3.56%1 Month Performance3.64%-0.08%3.52%2.54%1 Year Performance88.21%0.98%34.13%35.05% Oramed Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.8885 of 5 stars$3.99flatN/A+88.2%$163.29M$2M1.5410Gap UpAVTEAerovate TherapeuticsN/A$24.86-3.7%N/A+215.9%$720.57MN/AN/A20High Trading VolumeACRSAclaris Therapeutics2.2901 of 5 stars$4.88-1.4%$11.29+131.3%+258.7%$691.34M$7.83MN/A100GYREGyre Therapeutics2.2062 of 5 stars$7.30+3.0%$17.00+132.9%-30.2%$687.93M$116.59MN/A40News CoverageCYRXCryoPort3.1574 of 5 stars$13.04-1.0%$14.44+10.7%+131.8%$663.80M$176.18M9.661,186 Related Companies and Tools Related Companies Aerovate Therapeutics Competitors Aclaris Therapeutics Competitors Gyre Therapeutics Competitors CryoPort Competitors CytomX Therapeutics Competitors Sutro Biopharma Competitors Candel Therapeutics Competitors Tilray Brands Competitors Zevra Therapeutics Competitors Climb Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
